Heron Therapeutics, Inc. is a biotechnology firm that focuses on improving the lives of people suffering from illnesses like cancer by developing advanced treatments. Established in Delaware, Heron Therapeutics has its headquarters in California. It is traded under the ticker symbol "HRTX" on the NASDAQ Stock Exchange.
The company has been at the forefront of producing quality pharmaceutic solutions through its robust pipeline of products which includes SUSTOL® (granisetron) extended-release injection, CINVANTI® (aprepitant) injectable emulsion, and HTX-034, a novel, long-acting, extended-release formulation designed for postoperative pain management. Both SUSTOL® and CINVANTI® have been approved by the US FDA and have shown immense promise in the preventions of acute and delayed chemotherapy-induced nausea and vomiting (CINV).
Heron Therapeutics is developing HTX-019, an injectable emulsion of aprepitant, HTX-011, an extended-release local anesthetic, and zilucoplan, a macrocyclic peptide inhibitor of Complement component 5 (C5). The spectrum of its developmental programs demonstrates its commitment to addressing unmet medical needs and improving patient care.
The company is also pioneering in the arena of non-opioid-based therapies. Notably, HTX-011, their most advanced product candidate for postoperative pain, showed significantly reduced pain and need for opioid rescue medication following various types of surgery in several clinical trials. It has received breakthrough therapy and fast track designations from the FDA.
Heron also boasts an experienced and knowledgeable team, led by CEO Barry D. Quart. The management’s strong sector-specific expertise is a strong driver for Heron’s academic, clinical, and commercial endeavors. Its solid commitment to bringing groundbreaking therapeutic options to patients is matched by a similar resolve to benefit its shareholders.
While Heron Therapeutics has already achieved impressive feats in the biotechnology industry, it has only scratched the surface of its potential. Continued investments in research and development supplement the company's ongoing commitment to unlocking novel products that can transform outcomes for patients worldwide.
As a company operating within a rapidly evolving and competitive space, Heron Therapeutics, Inc. dedicates itself to integrity, collaboration, tenacity, and innovation. Through this culture, it aims to transform how supportive care is implemented in cancer treatment and continue its legacy in patient care. As such, HRTX represents an intriguing investment opportunity within the biotech sector.